Caplin Point Laboratories Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Caplin Point Laboratories is de winst gegroeid met een gemiddeld jaarlijks percentage van 19%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 16.3% per jaar. Het rendement op eigen vermogen van Caplin Point Laboratories is 19.3%, en het heeft een nettomarge van 26.9%.
Belangrijke informatie
19.0%
Groei van de winst
19.0%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 16.3% |
| Rendement op eigen vermogen | 19.3% |
| Nettomarge | 26.9% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10
With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 31Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50
Sep 12Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50
Aug 10Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings
Jul 12Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Opbrengsten en kosten
Hoe Caplin Point Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 18,328 | 4,936 | 1,580 | 737 |
| 30 Jun 24 | 17,577 | 4,776 | 1,487 | 0 |
| 31 Mar 24 | 16,961 | 4,571 | 1,437 | 737 |
| 31 Dec 23 | 16,318 | 4,376 | 1,430 | 632 |
| 30 Sep 23 | 15,683 | 4,179 | 1,408 | 632 |
| 30 Jun 23 | 15,157 | 3,947 | 1,396 | 0 |
| 31 Mar 23 | 14,683 | 3,763 | 1,371 | 632 |
| 31 Dec 22 | 14,182 | 3,532 | 1,314 | 593 |
| 30 Sep 22 | 13,724 | 3,307 | 1,262 | 593 |
| 30 Jun 22 | 13,153 | 3,140 | 1,210 | 0 |
| 31 Mar 22 | 12,710 | 2,998 | 1,154 | 593 |
| 31 Dec 21 | 12,099 | 2,872 | 1,110 | 537 |
| 30 Sep 21 | 11,581 | 2,767 | 1,071 | 537 |
| 30 Jun 21 | 11,217 | 2,586 | 1,034 | 0 |
| 31 Mar 21 | 10,624 | 2,423 | 1,026 | 537 |
| 31 Dec 20 | 9,986 | 2,248 | 952 | 530 |
| 30 Sep 20 | 9,524 | 2,189 | 874 | 530 |
| 30 Jun 20 | 9,107 | 2,193 | 780 | 0 |
| 31 Mar 20 | 8,640 | 2,150 | 678 | 530 |
| 31 Dec 19 | 8,356 | 2,159 | 617 | 282 |
| 30 Sep 19 | 7,664 | 2,032 | 557 | 282 |
| 30 Jun 19 | 6,948 | 1,894 | 512 | 0 |
| 31 Mar 19 | 6,490 | 1,766 | 471 | 282 |
| 31 Dec 18 | 6,048 | 1,621 | 449 | 237 |
| 30 Sep 18 | 5,874 | 1,538 | 431 | 237 |
| 30 Jun 18 | 5,628 | 1,459 | 417 | 0 |
| 31 Mar 18 | 5,399 | 1,448 | 391 | 237 |
| 31 Dec 17 | 5,145 | 1,430 | 367 | 141 |
| 30 Sep 17 | 4,757 | 1,297 | 352 | 141 |
| 30 Jun 17 | 4,401 | 1,165 | 322 | 0 |
| 31 Mar 17 | 4,016 | 956 | 321 | 141 |
| 31 Dec 16 | 3,655 | 783 | 300 | 54 |
| 30 Sep 16 | 3,420 | 703 | 274 | 54 |
| 30 Jun 16 | 3,238 | 619 | 258 | 54 |
| 31 Mar 16 | 3,088 | 584 | 240 | 54 |
| 31 Dec 15 | 2,906 | 535 | 298 | 67 |
| 30 Sep 15 | 2,722 | 465 | 283 | 60 |
| 30 Jun 15 | 2,518 | 410 | 203 | 59 |
| 31 Mar 15 | 2,296 | 353 | 233 | 53 |
| 31 Dec 14 | 2,074 | 318 | 220 | 42 |
| 30 Sep 14 | 1,893 | 305 | 204 | 33 |
| 30 Jun 14 | 1,731 | 258 | 190 | 21 |
| 31 Mar 14 | 1,643 | 204 | 166 | 4 |
| 31 Dec 13 | 1,517 | 167 | 149 | 0 |
Kwaliteitswinsten: CAPLIPOINT heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (26.9%) CAPLIPOINT } zijn hoger dan vorig jaar (26.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van CAPLIPOINT is de afgelopen 5 jaar met 19% per jaar gegroeid.
Versnelling van de groei: De winstgroei van CAPLIPOINT over het afgelopen jaar ( 18.1% ) ligt onder het 5-jarig gemiddelde ( 19% per jaar).
Winst versus industrie: De winstgroei CAPLIPOINT over het afgelopen jaar ( 18.1% ) overtrof de Pharmaceuticals -sector 20.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 19.3% ) van CAPLIPOINT wordt als laag beschouwd.